Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223282 | 0.87 | CA14 (0.48) | CA14POLBMEN1KMT2ACA12 | |
| SCHEMBL5464993 | 0.85 | CA14 (0.80) | CA14ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL10231797 | 0.84 | CA14 (0.78) | CA14ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL3574542 | 0.81 | TDP1 (0.50) | CA14MEN1KMT2AEPHX1CA12 | |
| SCHEMBL1631023 | 0.81 | CA14 (0.42) | CA14ALDH1A1SMN1; SMN2FPR3FPR2 | |
| SCHEMBL5070506 | 0.81 | CA14 (0.42) | CA14MEN1KMT2ACA12CA7 | |
| SCHEMBL24215034 | 0.81 | CA14 (0.69) | CA14ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL13567947 | 0.81 | CA14 (0.61) | CA14ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL25932928 | 0.80 | CA14 (0.72) | CA14ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6946470 | 0.80 | CA14 (0.76) | CA14ALDH1A1POLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557979-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557979-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | FOB SYNTHESIS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8232268-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC., (US) | 2010-06-24 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7683049-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2134343-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1126838-A4 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1456203-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| US-6586475-B1 | 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| WO-2003051872-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-26 | — | — | WO | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1126838-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025776-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | CA14 1147/4885ALDH1A1 1076/4885POLB 3012/4885 |
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | MGAM, GSK3B, GSK3A | CA14 1340/4885ALDH1A1 3694/4885POLB 337/4885 |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | MGAM, GSK3B, GSK3A | CA14 1340/4885ALDH1A1 3694/4885POLB 337/4885 |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | CA14 2679/4885ALDH1A1 360/4885POLB 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.